Apheresis: Principles and Technology of Hemapheresis

Rossi's Principles of Transfusion Medicine: Fourth Edition

Volumn , Issue , 2009, Pages 617-628

  Gilcher, Ronald O ^a   Smith, James W ^a  

^a Oklahoma Blood Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991434392     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303513.ch41     Document Type: Chapter

References (48)

1. Huestis DW, Bove JR, Busch S. Practical blood transfusion. 3rd ed. Boston, MA: Little, Brown, 1981:315-72.
2. Barnes A. Hemapheresis perspectives. In: Kolins J, Jones JM, eds. Therapeutic apheresis. Bethesda, MD: AABB, 1983:1-13.
3. Robert P. International directory of plasma fractionators. Orange, CT: Marketing Research Bureau, 2007.
4. Department of Health and Human Services. The 2007 National Blood Collection and Utilization Survey Report. Washington, DC: DHHS, 2008.
5. Simon T, Lee EJ, Heaton A, et al. Storage and transfusion of platelets collected by an automated two-stage apheresis procedure. Transfusion 1992;32:624-8.
6. Zingsem J, Strasser E, Ringwald J, et al. Evaluation of a new apher- esis system for the collection of leukoreduced single-donor platelets. Transfusion 2007;47:987-94.
7. Murphy MF, Seghatchian J, Krailadsiri P, et al. Evaluation of COBE Trima for the collection of blood components with particular reference to the in vitro characteristics of the red cell and platelet concentrates and the clinical responses to transfusion. Transfus Sci 2000;22:39-43.
8. Simon TL. The collection of platelets by apheresis procedures. Transfus Med Rev 1994;8:132-45.
9. Klein HG. It seemed a pity to throw away the red cells: Selective component collection (editorial). Transfusion 1993;33:788-90.
10. Meyer D, Bolgiano DC, Sayers M, et al. Red cell collection by apheresis technology. Transfusion 1993;33:819-24.
11. Smith JW, Gilcher RO. Red blood cells, plasma, and other new apheresis-derived blood products: Improving product quality and donor utilization. Transfus Med Rev 1999;13:118-23.
12. Minoz J, Clavo M, Garcia O, et al. Adsorptive monocyte and granulocyte apheresis in the chronic inflammatory illness: Ulcerative colitis, Crohn's disease, rheumatoid arthritis and Behcet syndrome. ISBT Science Series 2007;2:96-101.
13. Bosch T. State of the art of lipid apheresis. Artif Organs 1996;20:292-5
14. Bosch T. Lipid apheresis: From a heroic treatment to routine clinical practice. Artif Organs 1996;20:414-9.
15. Code of federal regulations. Title 21 CFR 640.65. Washington, DC: US Government Printing Office, 2008 (revised annually).
16. Winters J. Complications of donor apheresis. J Clin Apher 2006;21:132-41.
17. Newman BH. Donor reactions and injuries from whole blood donation. Transfus Med Rev 1997;11:64-75.
18. Huestis DW. Adverse effects in donors and patients subjected to hemapheresis. J Clin Apher 1984;2:81-90.
19. Simon TL, Moore RC, Sierra ER, et al. Storage of platelets from a new cell separator in a citrate-plasticized container. In: Rock G, ed. Apheresis. New York: Wiley-Liss, 1990:11-14.Price TH, ed. Standards for blood banks and transfusion services, 25th ed. Bethesda, MD: AABB, 2008.
20. Strauss RG. Effects on donors of repeated leukocyte losses during plateletpheresis. J Clin Apher 1994;9:130-4.
21. Katz L, Palmer K, McDonnell E, Kabat A. Frequent plateletpheresis does not clinically significantly decrease platelet counts in donors. Transfusion 2007;47:1601-6.
22. Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625-8.
23. Brand A. Passenger leukocytes, cytokines, and transfusion reactions (editorial). N Engl J Med 1994;331:670-1.
24. Dzik WH. Effects on recipients of exposure to allogeneic donor leukocytes. J Clin Apher 1994;9:135-8.
25. Shi PA, Ness PM. Two unit red cell apheresis and its potential advantages over traditional whole-blood donation. Transfusion 1999;39:218-25.
26. National Institutes of Health Consensus Conference. Fresh-frozen plasma: Indications and risks. JAMA 1985;253:551-3.
27. Herzig RH. Granulocyte transfusion therapy: Past, present, and future. In: Garratty G, ed. Concepts in transfusion therapy. Bethesda, MD: AABB, 1985:267-94.
28. Price TH. The current prospects for neutrophil transfusions for the treatment of granulocytopenic infected patients. Transfus Med Rev 2000;14:2-11.
29. Bandarenko N, Owen HG, Mair DC, et al. Apheresis: New opportunities. Clin Lab Med 1996;16:907-29.
30. Norol F, Scotto F, Duedari N, et al. Peripheral blood stem cell collection with a blood cell separator. Transfusion 1993;33:894-7.
31. Leibundgut K, Muff J, Hirt A, et al. Evaluation of the Fresenius cell separator AS 104 for harvesting peripheral blood stem cells in pediatric patients. Transfus Sci 1994;15:93-9.
32. Hester JP, Wallerstein RO. Peripheral blood stem cell transplantation for breast cancer patients with bone marrow metastases using GM- CSF priming. Transfus Sci 1993;14:65-9.
33. Wiltbank TB, Giordano GF. The safety profile of automated collections: An analysis of more than 1 million donations. Transfusion 2007;47:1002-5.
34. Bueno JL. Do we really know the real risks of apheresis donations. ISBT Science Series 2007;2:68-74.
35. Hester JP, McCullough J, Mishler JM, et al. Dosage requirements for citrate anticoagulants. J Clin Apher 1983;1:149-57.
36. Olson PR, Cox C, McCullough J. Laboratory and clinical effects of the infusion of ACD solution during plateletpheresis. Vox Sang 1987;33:79-87.
37. Williamson LM, Stainsby D, Jones H, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus- host disease. Transfusion 2007;47:1455-67.
38. Schrezenmeier H, Walther-Wenke G, Muller TH, et al. Bacterial contamination of platelet concentrates: Results of a prospective multicenter study comparing pooled whole-blood-derived platelets and apheresis platelets. Transfusion 2007;47:644-52.
39. Chopek M, McCullough J. Protein and biochemical changes during plasma exchange. In: Berkman EM, Umlas J, eds. Therapeutic hema- pheresis. Bethesda, MD: AABB, 1980:13-52.
40. Heaton A, Holme S. Blood donation and red cell volume (RCV) regeneration in donors of different weights (abstract). Vox Sang 1994;67(Suppl):13.
41. Holme S, Heaton A. Red cell volume (RCV) distribution in volunteers: implications for eligibility for two-unit red cell donation (abstract). Transfusion 1994;34(Suppl):S58.
42. Agdokan M, Camci C, Gurakar A, et al. The effect of total plasma exchange on fulminant hepatic failure. Clin Apher 2006;21:96-9.
43. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-7.
44. Heger A, Kannicht C, Romisch J, Svae TE. Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development. Vox Sang 2007;92:206-12.
45. Scully M, Longair I, Flynn M, et al. Cryo supernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007;93:154-8.
46. Weinstein R, Sato PTS, Shelton K, et al. Successful management of paraprotein-associated peripheral polyneuropathies by immunoadsorp- tion of plasma with staphylococcal protein A. J Clin Apher 1993;8:72-7.
47. Rook AH, Wolfe JT. Role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection. J Clin Apher 1994;9:28-30.
48. Edelson RL. Photopheresis. J Clin Apher 1990;5:77-9.